Table 2.

Subsequent breast cancer risk in women with AH and CCL

Type of benign breast disease	No. of Patients (%)*	No. of cases	Cancer incidence rate†	Relative risk	95% CI	P-value
No PD or CCL	1966	67	224	1‡
AH, no CCL	108 (3.3)	10	802	3.24	1.6–6.5	0.001
AH + CCL	107 (8.5)	14	1152	5.01	2.7–9.1	< 0.0005
ALH, no CCL	69 (2.1)	9	1079	4.28	2.1 – 8.8	< 0.0005
ALH + CCL	70 (5.6)	13	1643	6.97	3.8 – 13	< 0.0005
ADH, no CCL	46 (1.4)	4	868	3.31	1.2 – 9.4	0.02
ADH + CCL	44 (3.5)	4	813	3.46	1.2 – 9.7	0.02
AH, no CCL	108 (3.3)	10	802	1‡
AH + CCL	107 (8.5)	14	1152	1.55	0.69 – 3.5	0.29

AH indicates atypical hyperplasia; CCL, columnar cell lesions; CI, confidence interval; PD, proliferative disease; ALH, atypical lobular hyperplasia; ADH, atypical ductal hyperplasia.

^*Each percentage is the proportion of AH patients among all patients either with or without CCL, respectively (e.g. in the third row 107/1261 = 8.5%).

^†Crude annual incidence of invasive breast cancer per 100,000

^‡Denominator of subsequent relative risk(s)